Published in Cancer on October 15, 1982
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66
Surgery for distant melanoma metastasis. Cancer J (2012) 1.03
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist (2010) 0.92
Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep (2012) 0.82
Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer (1985) 0.81
Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients. Langenbecks Arch Surg (2008) 0.80
Surgery as palliative treatment for distant metastases of melanoma. Ann Surg (1986) 0.77
Evidence suggesting that a chronic disease self-management program can improve health status while reducing hospitalization: a randomized trial. Med Care (1999) 14.08
Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care (2001) 8.95
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep (1966) 8.79
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother (1977) 7.24
Infections caused by Pseudomonas aeruginosa. Rev Infect Dis (1983) 7.19
Community education for cardiovascular health. Lancet (1977) 6.32
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol (1971) 5.23
Proceedings: Causes of death in cancer patients. Cancer (1974) 4.56
Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer (1972) 4.47
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother (1991) 4.36
Variation of the human menstrual cycle through reproductive life. Int J Fertil (1970) 4.26
A new international staging system for lung cancer. Chest (1986) 4.25
Macrophage-lymphocyte interaction in the antigen-induced blastogenic response of human peripheral blood leukocytes. J Immunol (1968) 4.25
The transformation of column-purified lymphocytes with nonspecific and specific antigenic stimuli. J Immunol (1968) 4.24
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
The Stanford Five-City Project: design and methods. Am J Epidemiol (1985) 4.06
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 4.02
Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 4.00
Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol (1994) 3.94
Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother (1988) 3.92
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med (1965) 3.54
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
In vitro activity of carbenicillin against gram-negative bacilli. J Bacteriol (1968) 3.41
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
A system for the clinical staging of lung cancer. Am J Roentgenol Radium Ther Nucl Med (1974) 3.29
Piperacillin: in vitro evaluation. Antimicrob Agents Chemother (1978) 3.21
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). Lancet Oncol (2001) 3.02
Anesthesia, pregnancy, and miscarriage: a study of operating room nurses and anesthetists. Anesthesiology (1971) 2.85
Physical activity outcomes of CHAMPS II: a physical activity promotion program for older adults. J Gerontol A Biol Sci Med Sci (2001) 2.79
Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis (2000) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med (1990) 2.72
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother (1980) 2.67
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis (2002) 2.63
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis (1993) 2.51
Candidiasis in cancer patients. Am J Med (1984) 2.48
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis (1991) 2.47
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother (1973) 2.47
PC-904, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.46
Carbenicillin therapy for pseudomonas infections. JAMA (1971) 2.40
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol (1971) 2.35
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci (1969) 2.25
Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother (1982) 2.23
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
In vitro evaluation of cefoperazone. Antimicrob Agents Chemother (1980) 2.22
Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry (1992) 2.20
Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med (1985) 2.17
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med (1993) 2.16
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Trichosporon beigelii infection: a review. Rev Infect Dis (1987) 2.15
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Minority cancer patients and their providers: pain management attitudes and practice. Cancer (2000) 2.13
Pirbenicillin, a new semisynthetic penicillin with broad-spectrum activity. Antimicrob Agents Chemother (1976) 2.12
Amoxicillin: in vitro and pharmacological studies. Antimicrob Agents Chemother (1972) 2.12
Infections in cancer patients. Cancer Treat Rev (1975) 2.12
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2001) 2.11
The rate of division of antibody-forming cells during the early primary immune response. J Exp Med (1968) 2.10
Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access. Arch Intern Med (1993) 2.10
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
Bacteremia caused by Campylobacter-like organisms in two male homosexuals. Ann Intern Med (1984) 2.07
Running and the development of disability with age. Ann Intern Med (1994) 2.05
Systemic candidiasis in cancer patients. Am J Med (1984) 2.05
Differences in preconceptional and prenatal behaviors in women with intended and unintended pregnancies. Am J Public Health (1998) 2.05
Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother (1981) 2.04
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. Arch Gen Psychiatry (1999) 2.03
Ticarcillin therapy of infections. Antimicrob Agents Chemother (1973) 2.01
Survival in early-stage non-small cell lung cancer. Ann Thorac Surg (1995) 2.01
Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother (1983) 2.00
Hereditary aspects of malignant melanoma. JAMA (1967) 1.98
Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med (2000) 1.95
Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids. Antimicrob Agents Chemother (1983) 1.93
Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A (1975) 1.92
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
Occupational disease in dentistry and chronic exposure to trace anesthetic gases. J Am Dent Assoc (1980) 1.90
Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer (2001) 1.89
Klebsiella bacteremia in cancer patients. Am J Med Sci (1973) 1.87
In vitro studies of BB-K8, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1973) 1.86
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med (1979) 1.86